Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. The company was founded in 1832 and is based in Rogers, Connecticut.
ROG Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for ROG, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Rogers Corp ranked in the 36th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 29.33%. As for the metrics that stood out in our discounted cash flow analysis of Rogers Corp, consider:
89% of the company's capital comes from equity, which is greater than 75.7% of stocks in our cash flow based forecasting set.
The business' balance sheet suggests that 11% of the company's capital is sourced from debt; this is greater than merely 24.26% of the free cash flow producing stocks we're observing.
As a business, Rogers Corp experienced a tax rate of about 14% over the past twelve months; relative to its sector (Technology), this tax rate is higher than 61.31% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ACN, APH, OSIS, YY, and TER can be thought of as valuation peers to ROG, in the sense that they are in the Technology sector and have a similar price forecast based on DCF valuation.
BCE Inc. (TSX:BCE)(NYSE:BCE) and the Canadian Big Three telecoms are now on sale amid the 5G boom, but are they worthy of your investment dollars? The post Better Buy: BCE (TSX:BCE), Telus (TSX:T), or Rogers (TSX:RCI.B)? appeared first on The Motley Fool Canada .
There is some renewed hope for rheumatoid arthritis drugs like Eli Lilly’s Olumiant and Roche’s Actemra as possible COVID-19 treatments after a series of clinical setbacks this summer seemed to close the door on the category’s potential.
Shares of Roche Holding AG gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than those receiving placebo. The Phase 3, randomized, double-blind, placebo-controlled study focused on enrolling minority patients with COVID-19-related pneumonia; there are 389 participants enrolled in the trial. However, the drug did not lead to a difference in mortality, Roche said. Roche is also testing Actemra with Gilead Sciences Inc.'s remdesivir, which is the only new drug to receive an emergency use authorization from the Food and Drug Administration as a COVID-19 treatment during the pandemic. Earlier this week Eli Lilly & Co. and Incyte Corp. said their ...
Seaborne imports to the U.S. set a record in August and were up 5.9% from the same period a year ago, according to a new report from Panjiva, the supply chain research unit of S&P Global Market Intelligence.